Eight year experience with the CarboMedics bileaflet valvular prosthesis.
Two hundred and two patients (97 female and 105 male; mean age: 45. 5+/-9 years) received CarboMedics bileaflet valves during a period of eight years. Ninety-one patients received mitral, 72 aortic and 39 aortic+mitral valve prosthesis. Tricuspid plasty and coronary artery bypass surgery were the concomitant operations in 17 and 12 patients, respectively. The mean follow-up period was 24.7 months and the ratio was 91%. Overall operative mortality was 3.96% (8 patients); 2.78% for aortic valve replacement (AVR), 3.29% for mitral valve replacement (MVR) and 7.7% for double valve replacement (DVR). The late mortality rate was 2.89% for AVR, 2.2% for MVR and 8. 3% for DVR. The main cause of mortality was low cardiac output. The overall survival rate was 91.5% in 2 years. The actuarial freedom from thromboembolism in 2 years was 97% for AVR, 95% for MVR and 84% for DVR. No mortality due to heamorrhagic events was observed. CarboMedics prosthetic heart valves may be used satisfactorily with a low incidence of valve-related morbidity and mortality.
Sinci
V
V
Department of Thoracic and Cardiovascular Surgery, Gazi University School of Medicine, Ankara, Turkey.
Halit
V
V
Kalaycioglu
S
S
Gunaydin
S
S
Imren
Y
Y
Gokgoz
L
L
Soncul
H
H
Eesoz
A
A
D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001021:Aortic Valve / Q000601:surgery; D002303:Cardiac Output, Low / Q000209:etiology; D002423:Cause of Death; D001026:Coronary Artery Bypass; D005260:Female; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery; D019106:Postoperative Hemorrhage / Q000209:etiology; D011474:Prosthesis Design; D015996:Survival Rate; D013923:Thromboembolism / Q000209:etiology; D014261:Tricuspid Valve / Q000601:surgery